Co-sulfamethoxazole Tablets

This product is a compound preparation, each tablet contains the active ingredients 0.4g of sulfamethoxazole and 0.08g of trimethoprim.

This product is white tablets.

The usual dosage for children is contraindicated for infants under 2 months old. For the treatment of bacterial infections, infants and young children over 2 months old and weighing less than 40 kg should take SMZ 20-30 mg/kg and TMP 4-6 mg/kg orally once every 12 hours; the dosage for children weighing 40 kg is the same as the usual dosage for adults. For the treatment of parasitic infections such as Pneumocystis carinii pneumonia, take SMZ 18.75-25 mg/kg and TMP 3.75-5 mg/kg orally once every 6 hours, for a course of 14 to 21 days. The course of treatment for acute attacks of chronic bronchitis is at least 10 to 14 days; the course of treatment for urinary tract infections is 7 to 10 days; the course of treatment for bacillary dysentery is 5 to 7 days; the course of treatment for acute otitis media in children is 10 days.

1. Allergic reactions are relatively common and may manifest as drug rashes. In severe cases, exudative erythema multiforme, exfoliative dermatitis, and epidermolysis bullosa atrophic dermatitis may occur; there are also serum sickness-like reactions such as photosensitivity reactions, drug fever, joint and muscle pain, and fever. Anaphylactic shock is occasionally seen. 2. Neutropenia or deficiency, thrombocytopenia, and aplastic anemia. Patients may present with sore throat, fever, pallor, and bleeding tendency. 3. Hemolytic anemia and hemoglobinuria. This is prone to occur in patients who lack glucose-6-phosphate dehydrogenase after using sulfonamides, and is more common in newborns and children than in adults. 4. Hyperbilirubinemia and neonatal kernicterus. Because this product competes with bilirubin for protein binding sites, it can cause an increase in free bilirubin. Newborns have imperfect liver function and are sensitive to bilirubin.

1. Patients who are allergic to SMZ and TMP are contraindicated to use this product. 2. Since this product blocks the metabolism of folic acid and aggravates the folate deficiency in patients with megaloblastic anemia, this product is contraindicated for patients with this disease. 3. Infants under 2 months old are contraindicated to use this product. 4. Patients with severe liver and kidney damage are contraindicated to use this product.

Precautions for children: Since this product can compete with bilirubin for binding sites on plasma proteins, and the acetyltransferase system of newborns is not fully developed, the free blood concentration of sulfonamide increases, which increases the risk of kernicterus. Therefore, the use of this type of drug in newborns and infants under 2 months old is contraindicated. Children are in the growth and development period, and their liver and kidney functions are not yet perfect, so the dosage should be reduced as appropriate. Precautions for pregnancy and lactation: 1. This product can cross the blood-placental barrier to the fetus, and animal experiments have found that it has teratogenic effects. There is a lack of sufficient data in human studies, and pregnant women should avoid using it. 2. This product can be secreted in breast milk, and the concentration in breast milk can reach about 50% to 100% of the maternal blood drug concentration. The drug may affect the baby. The use of this product in newborns with glucose-6-phosphate dehydrogenase deficiency may lead to hemolytic anemia. In view of the above reasons, this product should not be used by lactating women. Elderly patients are more likely to experience serious adverse reactions when using this product: such as severe skin allergic reactions such as rash, and blood system abnormalities such as bone marrow suppression, leukopenia and thrombocytopenia. It is more likely to occur when using diuretics at the same time. Therefore, elderly patients should avoid using this product. If there is an indication, the decision should be made after weighing the pros and cons.

1. The combined use of urine alkalinizing drugs can increase the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with para-aminobenzoic acid. Para-aminobenzoic acid can replace this product and be taken up by bacteria, and the two are antagonistic to each other. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action time or toxic reactions. Therefore, when these drugs are used at the same time as this product, or when used after the application of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. The combined use with bone marrow suppressive drugs may enhance the adverse reactions of such drugs on the hematopoietic system. Such as leukopenia, thrombocytopenia, etc. If there is an indication to use the two drugs together, the possible toxic reactions should be closely observed.

Keep away from light and store in sealed container.

0.48g*12s

24 months

Tiansheng Pharmaceutical Group Co., Ltd.

• Founded in:

  2001-10-16

• Address:

  Chongqing Chaoyang Industrial Park (Dianjiang Guixi)

• Tax NO.:

  9150000073397948XL

• Registered Funds:

  318 million yuan

• Website:

  Log in to view

• Email:

  Log in to view